Sichuan Huiyu Pharmaceutical Co., Ltd

This early-stage study is testing a new drug called HY07121 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose, check for side effects, and see if the drug shows any early signs of shrinking tumors. The…

This study is testing a new drug called HY05350 for people with advanced solid tumors that have a specific protein called MSLN. The first part checks the drug's safety and finds the right dose, while the second part looks at how well it shrinks tumors. It's for adults whose cance…

This early-stage study is testing a new experimental drug called HYP-6589 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it might he…

This study is testing a new drug, HYP-2090PTSA, for people with advanced solid tumors that have a specific genetic change called a KRAS mutation. The first part aims to find a safe and effective dose. The second part will explore how well the drug works for certain cancers with a…

This study is testing a new drug called HY0001a in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. It is for adults with cancers like esophageal cancer, lung cancer, an…

This is an early-stage study testing the safety of a new injectable drug, HY-2003, for reducing fat under the chin (a double chin). The study will enroll 30 adults with moderate to severe chin fullness to see how safe the drug is at different doses and how the body processes it. …